These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14703939)

  • 1. Potency and durability of antiretroviral therapy.
    Daar ES
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S111-7. PubMed ID: 14703939
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing the benefits of antiretroviral therapy.
    Gulick RM
    Ann Intern Med; 2000 Sep; 133(6):471-3. PubMed ID: 10975966
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T-cell gain with nonnucleoside or protease inhibitors: convenience may not always be the most convenient.
    Barreiro P; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):758-60; author reply 760-1. PubMed ID: 15167297
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
    d'Ettorre G; Mastroianni CM; Massetti AP; Lichtner M; D'Agostino C; Vullo V
    AIDS; 2005 May; 19(8):841-2. PubMed ID: 15867503
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
    Fätkenheuer G; Römer K; Kamps R; Salzberger B; Burger D
    AIDS; 2001 Nov; 15(17):2334-5. PubMed ID: 11698713
    [No Abstract]   [Full Text] [Related]  

  • 9. CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
    Wood E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):347-8. PubMed ID: 14600584
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses.
    Maggiolo F; Callegaro A; Gregis G; Quinzan G; Ripamonti D; Arici C; Goglio A; Suter F
    AIDS; 2002 Jan; 16(2):298-9. PubMed ID: 11807319
    [No Abstract]   [Full Text] [Related]  

  • 11. Protease inhibitors: opium of the masses?
    Martinez LJ
    Res Initiat Treat Action; 2000 Sep; 6(3):7-11. PubMed ID: 11708167
    [No Abstract]   [Full Text] [Related]  

  • 12. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption.
    Barreiro P; de Mendoza C; González-Lahoz J; Soriano V
    Clin Infect Dis; 2005 Sep; 41(6):897-900. PubMed ID: 16107992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
    Höring S; Löffler B; Pletz MW; Rößler S; Weis S; Schleenvoigt BT
    Infection; 2018 Oct; 46(5):599-605. PubMed ID: 29961209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral rounds. Reason to be worried.
    Henry K; Hicks C
    AIDS Clin Care; 2000 Oct; 12(10):82-3. PubMed ID: 12211167
    [No Abstract]   [Full Text] [Related]  

  • 16. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 17. Using databases for clinical outcomes.
    Clay PG
    AIDS; 2002 Jan; 16(2):300-3. PubMed ID: 11807321
    [No Abstract]   [Full Text] [Related]  

  • 18. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection.
    Kahlert C; Hupfer M; Wagels T; Bueche D; Fierz W; Walker UA; Vernazza PL
    AIDS; 2004 Apr; 18(6):955-7. PubMed ID: 15060447
    [No Abstract]   [Full Text] [Related]  

  • 19. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.